Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1487940
This article is part of the Research Topic Combination Therapies in Cancer Treatment: Enhancing Efficacy and Reducing Resistance View all articles

Concurrent Immune Checkpoint Blockade for Enhanced Cancer Immunotherapy Utilizing Engineered Hybrid Nanovesicles

Provisionally accepted
Yuxuan Liu Yuxuan Liu 1Fuxu Yang Fuxu Yang 2Zhimin Li Zhimin Li 2Ting Wang Ting Wang 3Yeteng Mu Yeteng Mu 2Yuxin Fan Yuxin Fan 2Han Xue Han Xue 2Lili Huang Lili Huang 2Xingang Guan Xingang Guan 3*Hongxia Feng Hongxia Feng 1
  • 1 First People's Hospital of Wenling, Wenling, China
  • 2 Beihua University, Jilin, Jilin Province, China
  • 3 Taizhou University, Taizhou, China

The final, formatted version of the article will be published soon.

    Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, demonstrating unprecedented efficacy against advanced cancers. However, their clinical applications are significantly hampered by low overall response rates. Dual blockade of two immune checkpoints represents a promising strategy to enhance immunotherapeutic efficacy. In this study, we developed hybrid cell membrane nanovesicles adorned with PD-1 and SIRPα receptors for combination immunotherapy in melanoma. Our hybrid nanovesicles (PD-1/SIRPα NVs) demonstrated high specificity to PD-L1 and CD47 ligands, facilitating the phagocytosis of melanoma cells by macrophages. In a melanoma mouse model, PD-1/SIRPα NVs significantly suppressed 77% of tumor growth and elicited a robust antitumor immune response for immunotherapy. In conclusion, our findings highlight the promising potential of PD-1/SIRPα NVs as novel and effective ICIs for cancer immunotherapy.

    Keywords: PD-1, SIRPα, cell membrane nanovesicle, Immune checkpoint blockade, cancer immunotherapy

    Received: 29 Aug 2024; Accepted: 30 Oct 2024.

    Copyright: © 2024 Liu, Yang, Li, Wang, Mu, Fan, Xue, Huang, Guan and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xingang Guan, Taizhou University, Taizhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.